e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
William W. Busse, Monica Kraft, Klaus F. Rabe, Yamo Deniz, Paul J. Rowe, Marcella Ruddy, Mario Castro
Source:
Eur Respir J, 58 (2) 2003393; 10.1183/13993003.03393-2020
Journal Issue:
August
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
William W. Busse, Monica Kraft, Klaus F. Rabe, Yamo Deniz, Paul J. Rowe, Marcella Ruddy, Mario Castro. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J, 58 (2) 2003393; 10.1183/13993003.03393-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
The role of infections in the induction of asthma: genetic and inflammatory drivers
Source: Annual Congress 2007 - PG24 - GRACE full-day course. From cough to asthma: the role of infection
Year: 2007
Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
Source: Eur Respir Rev 2015; 24: 594-601
Year: 2015
The role of biomarkers in the management of severe asthma
Source: International Congress 2019 – Severe asthma guidelines: update 2019
Year: 2019
Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms
Source: Eur Respir J 2007; 29: 793-803
Year: 2007
Metabolic consequences of obesity as an “outside in” mechanism of disease severity in asthma
Source: Eur Respir J 2016; 48: 291-293
Year: 2016
Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma
Source: Annual Congress 2005 - Mechanisms of resolution of inflammation
Year: 2005
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma
Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021
Year: 2021
Evidence of early abnormal airways’ inflammation in children with type 1 diabetes
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice
Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019
Year: 2020
Are a degree of asthma therapy related to asthma control impairment?
Source: Eur Respir J 2003; 22: Suppl. 45, 370s
Year: 2003
Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Overview and history of different ways of assessing and monitoring inflammatory airway diseases
Source: International Congress 2017 – PG6 Assessing and monitoring airway inflammation in asthma and chronic obstructive pulmonary disease
Year: 2017
The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options
Source: International Congress 2015 – The challenge of treating uncontrolled asthma on Step 3 and higher: Comparing options
Year: 2015
Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020
Current control, airway inflammation, and subsequent exacerbation in patients with asthma
Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring
Year: 2010
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept